MNOV Projected Dividend Yield
Medicinova Inc ( NASDAQ : MNOV )MediciNova, Inc. is a biopharmaceutical company focused on developing treatments for serious diseases with unmet medical needs, primarily targeting the U.S. market. Key developments include MN-166 (ibudilast) for neurological disorders like progressive multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS), as well as substance dependence and Long COVID. MN-001 (tipelukast) targets fibrotic diseases such as nonalcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). The pipeline also includes MN-221 for acute asthma exacerbation and MN-029 for solid tumor cancers. 21 YEAR PERFORMANCE RESULTS |
MNOV Dividend History Detail MNOV Dividend News MNOV Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |